Clinical Trial Update: Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis

View source ↗

Summary

A clinical trial evaluating bortezomib for immunoglobulin light chain (AL) amyloidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Light Chain Amyloidosis

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Zhi-Hong Liu, M.D. | Conditions: Amyloidosis | Status: COMPLETED